Kraj: Izrael
Język: angielski
Źródło: Ministry of Health
DACARBAZINE
PROPHARM LTD
L01AX
POWDER FOR SOLUTION FOR INJ/INF
DACARBAZINE 200 MG/VIAL
I.V, INTRA-ARTERIAL
Required
LIPOMED AG, SWITZERLAND
OTHER ALKYLATING AGENTS
For the treatment of metastatic malignant melanoma, Hodgkin's disease as a second line therapy when used in combination with other agents.
2022-11-30
Page 1 of 6 1. NAME OF THE MEDICINAL PRODUCT DACARBAZINE-DACIN 200 mg 2. COMPOSITION Active substance: Dacarbazine. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Vial containing 200 mg dacarbazine powder for solution for injection/infusion. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Metastatic, malignant melanoma. Hodgkin’s disease as a second line therapy when used in combination with other agents. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Unless specific dosage guidelines for combination therapy have been specified, the following dosage regimens are to be followed, particularly for monotherapy: 4 - 5 day cycles of 150 to 250 mg/m2 body surface area/day I.V. This treatment can be repeated every 21 days. Alternatively, 2.0-4.5 mg/kg/day I.V may be given for 1-10 days. This regimen can be repeated every 28 days. DACARBAZINE- DACIN is administered either as an intravenous injection over approximately one minute or as an intravenous infusion over 15-30 minutes. If necessary, DACARBAZINE-DACIN can be given intra-arterially. COMBINATION CHEMOTHERAPY: generally 4 to 5 day cycles of 100 mg/m2/day, with a 21 day interval between subsequent cycles starting from the last day of treatment. For the preparation of the solution for injection/infusion, please refer to Section 6.4. Extravasation of DACARBAZINE-DACIN during intravenous administration can induce tissue damage and severe pain. 4.3. CONTRAINDICATIONS • Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1, • pregnancy or breastfeeding (see Section 4.6), • leukopenia and/or thrombocytopenia, • severe liver or kidney diseases. 4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE It is recommended that dacarbazine should only be administered under the supervision of a physician specialised in oncology who has the facilities for regular monitoring of clinical, biochemical and haematological effects, during and after therapy. If symptoms of a liver or kidney functional disorder or symptoms of a Przeczytaj cały dokument